Colm A. O’morain

Colm A. O’morain's AcademicInfluence.com Rankings

Colm A. O’morain

Philosophy

#5046

World Rank

#7758

Historical Rank

Logic

#2387

World Rank

#3371

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Colm A. O’morain's Degrees

Masters Medicine National University of Ireland
Doctorate Medicine National University of Ireland

Why Is Colm A. O’morain Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Colm A. O’morain's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease (2001) (5565)
Helicobacter pylori Infection (1994) (2472)
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report (2006) (2333)
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report (2012) (2271)
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report (2016) (2261)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. (2010) (1578)
Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report (2002) (1309)
CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. (2002) (996)
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). (1997) (898)
Newly identified genetic risk variants for celiac disease related to the immune response (2008) (697)
Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study (1996) (562)
CAMPYLOBACTER PYLORI AND RECURRENCE OF DUODENAL ULCERS— A 12-MONTH FOLLOW-UP STUDY (1987) (537)
Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) (2011) (533)
Geographical variability and environmental risk factors in inflammatory bowel disease (2013) (469)
European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations (2006) (449)
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. (1998) (424)
The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. (1999) (414)
Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) (2012) (374)
Diagnosis of Helicobacter pylori infection with a new non-in vasive antigen-based assay (1999) (344)
Treatment of Helicobacter pylori (1998) (288)
Antimicrobial Susceptibility Testing ofHelicobacter pylori in a Large Multicenter Trial: the MACH 2 Study (1999) (280)
Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. (2000) (262)
Absorption of 151chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease (1983) (253)
Treatment of Helicobacter pylori Infection (2006) (240)
E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided ‘Constant-care’ approach (2010) (235)
Sequential Therapy for Helicobacter pylori Eradication: A Critical Review (2010) (223)
Nature meets nurture: molecular genetics of gastric cancer (2009) (220)
Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. (2006) (219)
Reversible male infertility due to sulphasalazine: studies in man and rat. (1984) (208)
One week triple therapy for Helicobacter pylori: a multicentre comparative study (1997) (191)
Review article: defining remission in ulcerative colitis (2011) (190)
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease (2011) (182)
Does Pregnancy Change the Disease Course? A Study in a European Cohort of Patients with Inflammatory Bowel Disease (2006) (181)
Review article: the long‐term use of proton‐pump inhibitors (2005) (174)
Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting (2020) (164)
Criteria of case definition in Crohn's disease and ulcerative colitis. (1989) (163)
The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. (2006) (161)
Validation of the Capsule Endoscopy Crohn’s Disease Activity Index (CECDAI or Niv score): a multicenter prospective study (2011) (152)
Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. (1999) (152)
Colorectal Adenoma Characteristics as Predictors of Recurrence (2004) (141)
Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding (2000) (140)
Population screening and treatment of Helicobacter pylori infection (2017) (138)
Review article: nutrition and adult inflammatory bowel disease. (2003) (128)
Gastric epithelial cell kinetics in the progression from normal mucosa to gastric carcinoma. (1996) (127)
The GU‐MACH study: the effect of 1‐week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer (1999) (127)
Crohn’s disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort (2005) (125)
High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. (2013) (125)
Public awareness of risk factors and screening for colorectal cancer in Europe (2004) (123)
Current therapeutic options for gastric antral vascular ectasia (2003) (123)
Treatment of Helicobacter pylori Infection (2008) (121)
Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study (2000) (119)
Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. (1997) (118)
Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. (2014) (115)
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report (2022) (115)
Lack of Effect of TreatingHelicobacter pyloriInfection in Patients with Nonulcer Dyspepsia (1998) (113)
Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia. (1991) (109)
Efficacy and safety of single‐triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study (2003) (108)
Rifabutin‐ and furazolidone‐based Helicobacter pylori eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patients (2005) (108)
Guidelines for clinical trials in Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. (1997) (106)
Vitamin D deficiency in Crohn's disease: prevalence, risk factors and supplement use in an outpatient setting. (2012) (103)
European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients (2020) (98)
Helicobacter pylori and duodenal ulcer recurrence. (1992) (96)
Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. (1990) (95)
Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. (1996) (94)
Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease. (1984) (94)
Treatment of Helicobacter pylori infection and factors influencing eradication (2002) (93)
Development of an index to define overall disease severity in IBD (2016) (92)
Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. (1996) (92)
The prevalence of genetic and serologic markers in an unselected European population‐based cohort of IBD patients (2007) (91)
Diagnosis of gluten‐sensitive enteropathy: is exclusive reliance on histology appropriate? (1998) (88)
Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe--an ECCO-EpiCom study. (2014) (87)
Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort (2014) (87)
Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up study (2006) (85)
Association of NOD2 with Crohn's Disease in a homogenous Irish population (2003) (84)
Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori (1994) (83)
Technical annex: tests used to assess Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. (1997) (82)
Recrudescence of Helicobacter pylori after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting. (1995) (81)
The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis (2015) (81)
Patient knowledge and educational needs in irritable bowel syndrome (2000) (79)
Recurrence of Helicobacter pylori Infection After Successful Eradication (Nature and Possible Causes) (1997) (77)
Treatment of Helicobacter pylori Infection 2010 (2010) (77)
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study (2015) (75)
Argon plasma coagulation as first‐line treatment for chronic radiation proctopathy (2004) (73)
Colon capsule endoscopy as possible filter test for colonoscopy selection in a screening population with positive fecal immunology (2014) (71)
Review: Improving compliance with Helicobacter pylori eradication therapy: when and how? (2009) (71)
Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial. (1988) (71)
Who should be treated for Helicobacter pylori infection? A review of consensus conferences and guidelines. (1997) (69)
IBD patients need in health quality of care ECCO consensus. (2008) (67)
Effects of vitamin antioxidant supplementation on cell kinetics of patients with adenomatous polyps. (1993) (67)
Nutrition in inflammatory bowel disease. (2006) (65)
Genomic DNA fingerprinting of clinical isolates of Helicobacter pylori using short oligonucleotide probes containing repetitive sequences. (1996) (63)
CARD4/NOD1 is not involved in inflammatory bowel disease (2003) (62)
Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: a Network Meta-Analysis. (2021) (61)
Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. (2003) (61)
Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis (2004) (59)
Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection (1997) (59)
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. (2019) (58)
Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis (1991) (57)
Vitamin D Status Is Associated with Intestinal Inflammation as Measured by Fecal Calprotectin in Crohn’s Disease in Clinical Remission (2015) (56)
Histological gastritis in duodenal ulcer: relationship to Campylobacter pylori and effect of ulcer therapy. (1988) (55)
Clinical efficacy of triple therapy in Helicobacter pylori-associated duodenal ulcer (1993) (55)
Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort: An ECCO-EpiCom Study (2015) (55)
Does cure of Helicobacter pylori infection induce heartburn (1998) (54)
Long-term prospective study ofHelicobacter pylori in nonulcer dyspepsia (2005) (53)
Helicobacter pylori and increased epithelial cell proliferation: a risk factor for cancer (1994) (53)
Therapy of Helicobacter pylori (2004) (53)
Current Concepts and Management (2000) (53)
Nutritional Therapy in Crohn's Disease (1998) (53)
Metronidazole Resistance Reduces Efficacy of Triple Therapy and Leads to Secondary Clarithromycin Resistance (1997) (52)
A validated dyspepsia symptom score. (1997) (52)
Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. (1983) (51)
Chromium 51-ethylenediaminetetraacetate test: a useful test in the assessment of inflammatory bowel disease. (1986) (50)
Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study (2001) (50)
Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation. (1995) (50)
Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease--an ECCO-EpiCom study. (2014) (49)
Treatment of Helicobacter pylori Infection 2013 (2013) (49)
Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception (2008) (48)
A community‐based study of the epidemiology of Helicobacter pylori infection and associated asymptomatic gastroduodenal pathology (1998) (48)
United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia (2021) (47)
Treatment of Helicobacter pylori Infection 2011 (2011) (47)
Omeprazole increases permeability across isolated rat gastric mucosa pre‐treated with an acid secretagogue (2002) (47)
The effect of bile acids on the growth and adherence of Helicobacter pylori (1991) (46)
Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland (2010) (46)
Lack of a relationship between Lewis antigen expression and cagA, CagA, vacA and VacA status of Irish Helicobacter pylori isolates. (1999) (45)
Isolated Active Ileitis: Is It a Mild Subtype of Crohn's Disease? (2013) (45)
Treatment of Helicobacter pylori infection 2012 (2012) (45)
Association of gastric disease with polymorphisms in the inflammatory-related genes IL-1B, IL-1RN, IL-10, TNF and TLR4 (2009) (44)
Review: Treatment of Helicobacter pylori Infection 2019 (2019) (44)
Treatment of Helicobacter pylori infection in 2018 (2018) (42)
Epithelial patchy necrosis in Crohn's disease. (1983) (42)
Common variation in the vitamin D receptor gene and risk of inflammatory bowel disease in an Irish case–control study (2011) (41)
Coeliac disease in Europe (2003) (41)
Consensus or confusion: a review of existing national guidelines on Helicobacter pylori-related disease. (1997) (40)
Prevalence of metronidazole-resistant helicobacter pylori in dyspeptic patients (1993) (40)
Prevalence of Helicobacter pylori in non-ulcer dyspepsia. (1995) (40)
Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens. (1995) (39)
Eradication of Helicobacter pylori: recent advances in treatment (2005) (39)
Haplotypes in the CTLA4 region are associated with coeliac disease in the Irish population (2006) (39)
Pre-formed urease activity of Helicobacter pylori as determined by a viable cell count technique--clinical implications. (1994) (37)
Protocol of the European Registry on the management of Helicobacter pylori infection (Hp‐EuReg) (2019) (37)
Analysis of drug resistance and virulence‐factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status? (2009) (36)
Eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. (1993) (36)
Helicobacter biology--discovery. (1998) (35)
Short report: treatment of Helicobacter pylori‐associated duodenal ulcer with omeprazole plus antibiotics (1993) (35)
Chromosome 5q candidate genes in coeliac disease: genetic variation at IL4, IL5, IL9, IL13, IL17B and NR3C1. (2005) (35)
Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples (2016) (35)
Therapeutic benefits of budesonide in gastroenterology (2010) (34)
Enhanced cultivation of Helicobacter pylori in liquid media. (1993) (34)
Helicobacter pylori Gastritis, the Unifying Concept for Gastric Diseases (2007) (33)
Internet-based data inclusion in a population-based European collaborative follow-up study of inflammatory bowel disease patients: description of methods used and analysis of factors influencing response rates. (2005) (33)
A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection (2019) (33)
Vitamin D status and cytokine levels in patients with Crohn's disease. (2011) (32)
Treatment of Helicobacter pylori Infection 2015 (2015) (32)
European Crohn’s and Colitis Organisation Topical Review on Environmental Factors in IBD (2016) (32)
Effect of oral calcium supplementation on colonie crypt cell proliferation in patients with adenomatous polyps of the large bowel (1993) (32)
Does Helicobacter pylori Eradication Affect Symptoms in Nonulcer Dyspepsia: A 5‐Year Follow‐Up Study (2002) (31)
Nutritional Therapy in Inflammatory Bowel Disease. (2004) (30)
Identification of genes regulated by prolonged acid exposure in Helicobacter pylori. (2001) (30)
Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer. (2013) (30)
Treatment of Helicobacter pylori infection 2017 (2017) (30)
Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght–Trinity College colorectal cancer screening programme with the faecal immunological test (2014) (30)
Barrett's esophagus and the presence of Helicobacter pylori. (1998) (29)
Nutritional therapy in inflammatory bowel diseas (2004) (29)
Safety of infliximab in 10 years of clinical practice (2011) (29)
Different management of Helicobacter pylori positive and negative patients with gastro-oesophageal reflux disease (1998) (28)
Digestive Function of the Stomach (2014) (28)
Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis. (2008) (28)
Effects of Smoking on Cure of Helicobacter pylori Infection and Duodenal Uulcer Recurrence in Patients Treated with Clarithromycin and Omeprazole (1997) (28)
Erythrocyte Mean Corpuscular Volume (MCV) Correlation with Thiopurine Methyl Transferase (TPMT) Activity in Inflammatory Bowel Disease (IBD) Patients Receiving Azathioprine (AZA)/6-Mercaptopurine (6MP) (2004) (27)
Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. (2021) (27)
Subcellular fractionation of rectal biopsy homogenates from patients with inflammatory bowel disease. (1985) (27)
Helicobacter Pylori: The Cancer Link (1996) (27)
Short report: high‐dose omeprazole and amoxycillin in the treatment of Helicobacter pylori‐associated duodenal ulcer (1993) (27)
European Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice (2020) (26)
Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: A project of the European Collaborative Study Group on Inflammatory Bowel Disease (2007) (26)
Treatment of Helicobacter pylori Infection 2014 (2014) (26)
Organelle pathology in ulcerative and Crohn's colitis with special reference to the lysosomal alterations. (1984) (26)
Clinical and economic outcomes in a population‐based European cohort of 948 ulcerative colitis and Crohn’s disease patients by Markov analysis (2009) (25)
Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel - EPACT II. (2009) (25)
Common polygenic variation in coeliac disease and confirmation of ZNF335 and NIFA as disease susceptibility loci (2015) (25)
Vitamin D: new roles and therapeutic potential in inflammatory bowel disease. (2012) (25)
Pylera® for the eradication of Helicobacter pylori infection (2009) (25)
Helicobacter pylori eradication therapy: a discrepancy between current guidelines and clinical practice (2000) (25)
The sequential therapy regimen for Helicobacter pylori eradication (2010) (25)
Double‐blind, Multicenter, Placebo‐Controlled Evaluation Of Clarithromycin And Omeprazole For Helicobacter Pylori‐Associated Duodenal Ulcer (1996) (25)
Short report: short‐term triple therapy for H. pylori‐associated duodenal ulcer disease (1992) (25)
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). (2021) (24)
Recommendations for a step‐wise comparative approach to the evaluation of new screening tests for colorectal cancer (2016) (24)
Health care and patients' education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study. (2014) (24)
The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori (1996) (24)
Effect of phenotype on health care costs in Crohn's disease: A European study using the Montreal classification. (2007) (24)
[European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years]. (2019) (24)
Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg) (2021) (24)
Can bacterial virulence factors predict antibiotic resistant Helicobacter pylori infection? (2018) (23)
[Gastric cancer: a long-term consequence of Helicobacter pylori infection?]. (1994) (23)
A historical perspective of Helicobacter gastroduodenitis and its complications. (2007) (23)
Challenges to Therapy in the Future (2000) (23)
Pathogenesis and host response in helicobacter pylori infections (1997) (23)
Comparison of tests for assessment of Helicobacter pylori eradication: results of a multi‐centre study using centralized facility testing (2000) (23)
Helicobacter pylori first‐line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp‐EuReg) (2020) (23)
Nonulcer dyspepsia. Current concepts and management. (2000) (22)
Noninvasive Diagnosis of Helicobacter pylori Infection: A Review (1997) (22)
Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease (2007) (22)
Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort—An ECCO-EpiCom Study (2017) (22)
Helicobacter pylori infection in elderly dyspeptic patients. (1991) (22)
The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease (2010) (22)
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report. (1998) (22)
Genetic Mechanisms and Aberrant Gene Expression during the Development of Gastric Intestinal Metaplasia and Adenocarcinoma (2007) (22)
Practical treatment of Helicobacter pylori: a balanced view in changing times (2014) (22)
Gastro-oesophageal reflux disease andHelicobacter pylori: an intricate relation (1999) (21)
Does nutritional therapy in inflammatory bowel disease have a primary or an adjunctive role? (1990) (21)
Ethical issues in endoscopy: patient satisfaction, safety in elderly patients, palliation, and relations with industry. Second European Symposium on Ethics in Gastroenterology and Digestive Endoscopy, Kos, Greece, July 2006. (2007) (21)
HpSA: Assessment of a new non-invasive diagnostic assay for helicobacter pylori infection in an Irish population (1999) (21)
Communication of information to patients with inflammatory bowel disease: A European Collaborative Study in a multinational prospective inception cohort. (2008) (21)
Helicobacter pylori resistance to current therapies (2019) (21)
Review – Treatment of Helicobacter pylori infection 2020 (2020) (21)
Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study (2018) (21)
Treatment inferred disease severity in Crohn's disease: Evidence for a European gradient of disease course (2007) (20)
Genotyping of cagA and vacA, Lewis antigen status, and analysis of the poly-(C) tract in the alpha(1,3)-fucosyltransferase gene of Irish Helicobacter pylori isolates. (2000) (20)
Carditis: All Helicobacter pylori or Is There a Role for Gastro-oesophageal Reflux? (2002) (20)
Sunshine is an Important Determinant of Vitamin D Status Even Among High‐dose Supplement Users: Secondary Analysis of a Randomized Controlled Trial in Crohn's Disease Patients (2019) (20)
Helicobacter pylori and dyspepsia. (1996) (20)
A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients (2016) (20)
Biochemical analysis of enzymic markers of inflammation in rectal biopsies from patients with ulcerative colitis and Crohn's disease. (1983) (20)
Elemental diets in the treatment of Crohn's disease (1979) (20)
Helicobacter pylori and gastric cancer. (1995) (20)
Barrett's Esophagus and the Presence of Helicobacter pylori (1998) (19)
Determination of the optimal transport system for Helicobacter pylori cultures. (1993) (19)
Yersinia frederiksenii infection and colonization in hospital staff. (1993) (19)
Trends in the management of gastro-oesophageal reflux disease. (1998) (19)
Colorectal cancer screening. (2006) (19)
Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 8th ed. Pathophysiology/Diagnosis/Management. (2007) (18)
Haplotype variation at the IBD5/SLC22A4 locus (5q31) in coeliac disease in the Irish population. (2004) (18)
In patients with Helicobacter pylori gastritis and functional dyspepsia, a biopsy from the incisura angularis provides useful diagnostic information. (2006) (18)
Helicobacter pylori infection in Europe: current perspectives (2013) (18)
The long-term effect of Helicobacter pylori on gastric mucosa (1994) (17)
Helicobacter pylori eradication--a surrogate marker for duodenal ulcer healing. (1996) (17)
The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. (2017) (17)
DOP001 European Crohn's and Colitis Organisation topical review on environmental factors in IBD. (2017) (17)
Workgroup II: the screening process. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002). (2005) (17)
Helicobacter pylori eradication: role of individual therapy constituents and therapy duration (2009) (16)
Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn’s Disease (2015) (16)
United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia (2021) (16)
Room for Improvement in the Treatment of Helicobacter pylori Infection (2021) (16)
Analysis of single nucleotide polymorphisms in the region of CLDN2-MORC4 in relation to inflammatory bowel disease. (2013) (16)
Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland (2010) (15)
Transportation of Helicobacter pylori cultures by optimal systems (1994) (15)
Bismuth quadruple regimen with tetracycline or doxycycline versus three‐in‐one single capsule as third‐line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp‐EuReg) (2020) (15)
[European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): The first results of Russian centers]. (2016) (15)
Primary prevention of colorectal cancer: are we closer to reality? (2010) (15)
A randomized–controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population (2015) (15)
Role of Helicobacter pylori in functional dyspepsia. (2006) (15)
Statistical annex: statistical aspects of clinical trials in Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. (1997) (15)
Culture ofHelicobacter pylori under aerobic conditions on solid media (1994) (14)
Consensus guidelines: agreement and debate surrounding the optimal management of Helicobacter pylori infection. (2000) (14)
CARD 4 / NOD 1 is not involved in inflammatory bowel disease (2002) (14)
Novel celiac disease genetic determinants related to the immune response (2009) (14)
Screening for colorectal cancer: what fits best? (2012) (14)
Effect of eradication ofHelicobacter pylori infection on gastric epithelial cell proliferation (1995) (14)
The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. (2017) (14)
Fish Oil in the Treatment of Ulcerative Colitis (1990) (14)
The ECP calcium fibre polyp prevention study preliminary report. ECP Colon Group. (1993) (14)
The long-term use of proton-pump inhibitors (2005) (14)
Temporomandibular joint dislocation: an unusual complication of upper gastrointestinal endoscopy (2000) (13)
Pretreatment antimicrobial susceptibility testing is not cost saving in the standard eradication of Helicobacter pylori. (2004) (13)
Treatment of Helicobacter pylori infection 2016 (2016) (13)
Methods and Economic Considerations: Group 1 Report. ESGE/UEGF Colorectal Cancer--Public Awareness Campaign. The Public/Professional Interface Workshop: Oslo, Norway, June 20 - 22, 2003. fulfillment corporate. (2004) (13)
Is sequential therapy superior to standard triple therapy for the treatment of Helicobacter pylori infection? (2009) (13)
Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort (2014) (12)
What is new in the management of Helicobacter pylori? (2008) (12)
Patient knowledge in inflammatory bowel disease (2000) (12)
Helicobacter Pylori Treatment Results in Slovenia in the Period 2013-2015 as a Part of European Registry on Helicobacter Pylori Management (2017) (12)
Dietary Antigens in Crohn's Disease: Antibodies to Porcine Pancreatic Amylase (2008) (12)
Impact of Helicobacter pylori on the management of dyspepsia in primary care (2006) (12)
Aspirin as a chemoprevention agent for colorectal cancer. (2012) (12)
Liquid diets for Crohn's disease (2001) (11)
The clinical significance of antimicrobial serologic responses within an Irish Crohn’s disease population (2013) (11)
Adherence to colorectal polyp surveillance guidelines: is there a ‘scope’ to increase the opportunities for screening? (2011) (11)
Risk factors in inflammatory bowel disease. (1989) (11)
Investigation of molecular markers in the diagnosis of refractory coeliac disease in a large patient cohort (2008) (10)
THE MAASTRICHT GUIDELINES AND OTHER INNOVATIONS (1997) (10)
Culture of the organisms and histochemical identification. (1988) (10)
Increased inos and nitrotyrosine expression in irritable bowel syndrome (IBS) (2000) (10)
The Medical Profession, Industry, and Continuing Medical Education: Finding the Balance That's Right for Patients. (2019) (10)
The role of area-level deprivation and gender in participation in population-based faecal immunochemical test (FIT) colorectal cancer screening. (2016) (10)
Moving forward from drug-centred to patient-centred research (2019) (10)
Improving surveillance for Barrett's oesophagus (2006) (10)
Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. (1999) (10)
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain (2020) (10)
Immunochemical faecal occult blood tests have superior stability and analytical performance characteristics over guaiac-based tests in a controlled in vitro study (2011) (10)
The burden of digestive disease across Europe: Facts and policies. (2019) (10)
The safety and efficacy of tripotassium dicitrato bismuthate (De‐Nol) maintenance therapy in patients with duodenal ulceration (1990) (10)
RIP2 polymorphisms in inflammatory bowel diseases. (2011) (9)
Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force (2020) (9)
Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis. (2009) (9)
15th United European Gastroenterology Week (2007) (9)
Nutritional treatments in inflammatory bowel disease (2001) (9)
Motion--Helicobacter pylori worsens GERD: arguments for the motion. (2002) (9)
Validation of serological tests forHelicobacter pylori infection in an Irish population (2000) (9)
Evaluation of 6 candidate genes on chromosome 11q23 for coeliac disease susceptibility: a case control study (2010) (9)
Identification of a new segment involved in cagA 3' region variation of Helicobacter pylori. (2002) (9)
The effects of blood on rapid urease testing forHelicobacter pylori in mucosal biopsies from the gastric antrum (2000) (8)
Assessment of the clinical significance of intestinal spirochaetosis (2008) (8)
Helicobacter pylori-induced duodenal ulcer frequently coincides with gastro-oesophageal reflux disease. (2002) (8)
Clinical and pathological implications of IgG antibody responses toHelicobacter pyloriand its virulence factors in non‐ulcer dyspepsia (2003) (8)
Detection of Phospholipases and Cytotoxic Activities of Helicobacter pylori (1993) (8)
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) (2022) (8)
Non‐steroidal anti‐inflammatory drugs and Helicobacter pylori (2000) (8)
Risk of adenomatous polyps and colorectal cancer in relation to serum antioxidants and cholesterol status (1991) (8)
Negative emotions and cancer fatalism are independently associated with uptake of Faecal Immunochemical Test-based colorectal cancer screening: Results from a population-based study. (2021) (8)
Non-disease related factors affecting health related quality of life (HRQOL) in inflammatory bowel disease (IBD)* (1998) (8)
Eosinophilic oesophagitis: an Irish experience (2011) (7)
Do non‐steroidal anti‐inflammatory drugs have an effect on gastric cell turnover? (1995) (7)
Test and treat or test and scope for Helicobacter pylori infection. Any change in gastric cancer prevention? (2003) (7)
Effectiveness of Antiinfectives (2005) (7)
European initiatives in colorectal cancer screening (2011) (7)
The problem ulcer: bleeding, perforation, Helicobacter pylori -negativity and intractability (1996) (7)
Nutritional therapy in ambulatory patients (1987) (7)
A descriptive follow-up study onHelicobacter pylori infection before and after exposition to a war area (1994) (7)
Helicobacter pylori and gastroesophageal reflux disease: to treat or not to treat? (2001) (7)
Dosage of colloidal bismuth subcitrate in duodenal ulcer healing and clearance of Campylobacter pylori (1990) (7)
Elemental diets and Crohn's disease. (1987) (7)
Will eradication of Helicobacter pylori improve symptoms of non-ulcer dyspepsia? More studies should have been included in meta-analysis. (2000) (7)
Evropeyskiy registr Helicobacter pylori (Hp-EuReg): analiz dannykh 2360 bol'nykh, poluchavshikh terapiyu pervoy linii v Rossii (2018) (7)
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases (2022) (6)
[European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan]. (2020) (6)
Recurrence of hepatic amebiasis after successful treatment with metronidazole. (1988) (6)
Gastric retention and wireless capsule endoscopy in adults: a modified technique for direct duodenal deployment (2010) (6)
European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia. (2018) (6)
[Comparative study of the primary lactase deficiency in two different adult populations (55 inhabitants of Nice and 55 Maghrebins) (author's transl)]. (1978) (6)
Food intolerance: Dietary treatments in functional bowel disorders (2003) (6)
5-Aminosalicylates in inflammatory bowel: disease: Choosing choosing the right dose (2001) (6)
Chemical gastritis induced by naproxen in the absence of Helicobacter pylori infection. (1995) (6)
Panel Discussion – Unresolved Issues (2000) (6)
H. pylori in asymptomatic people (1994) (6)
Computer-Assisted Propofol Administration (2010) (6)
Comparison between McCoy cell line and HeLa cell line for detecting Helicobacter pylori cytotoxicity: clinical and pathological relevance. (1999) (6)
The effect of colonic site of biopsy on cell proliferation profiles using BRDU incorporation as a measure of cell proliferation. (1992) (5)
Increased mucosal mast cells in irritable bowel syndrome (IBS) (1998) (5)
Randomized trial of tinzaparin, a low molecular weight heparin (LMWH), versus placebo in the treatment of mild to moderately active ulcerative colitis (2003) (5)
Fundic gland polyps: not so trivial entity and worth evaluation. (2004) (5)
Review article: non-steroidal anti-inflammatory drugs and Helicobacter pylori. (2000) (5)
Evaluation of different solid media used for cultivation of Helicobacter (Campylobacter) pylori. (1992) (5)
Helicobacter pylori Treatment Failure: The Rationale for Alternative Antibiotics (2016) (5)
Risk of Progression of Gastric Intestinal Metaplasia Is Significantly Greater When Detected in Both Antrum and Body (2020) (5)
Reversible male infertility induced by sulphasalazine (1985) (5)
Reinfection with Helicobacter pylori Due to Intrafamilial Clustering of the Organism (1993) (5)
Early Epithelial Lesions in Crohn’s Disease, Revealed by Electron Microscopy (1981) (5)
Early ultrastructural changes of antral mucosa with aspirin in the absence of Helicobacter pylori. (1995) (4)
Di V erent management for Helicobacter pylori positive and negative patients with gastro-oesophageal reflux disease ? (1998) (4)
Tu1328 Pan-European Registry on H. pylori Management (HP-EuReg): Interim Analysis of First- and Second-Line Treatments (2016) (4)
Su1133 Pan-European Registry on H. pylori Management (HP-EuReg): Bacterial Resistance (2015) (4)
Diet and Crohn's disease. (1987) (4)
Increased iNOS expression in irritable bowel syndrome (IBS) patients with stress related symptoms (2003) (4)
Altered cardia epithelial cell kinetics induced by Helicobacter pylori infection and gastro‐oesophageal reflux disease: possible malignant potential? (2003) (4)
Molecular Detection of Antibiotic-Resistant Helicobacter pylori. (2021) (4)
UEG Week 2016 Poster Presentations (2016) (4)
Nutritional support in Crohn's disease: current status and future directions. (1995) (4)
Population characteristics of IrishHelicobacter pylori isolates: a tRNA-associated locus (2000) (4)
M1115 Sequential Therapy for Helicobacter pylori Eradication: A Critical Review (2010) (4)
The use of cyclosporin in the management of acute exacerbations of inflammatory bowel disease (1995) (4)
Irish society of gastroenterology (1991) (4)
Ornithine decarboxylase G316A genotype and colorectal cancer risk (2011) (4)
Association of reactive arthropathy and Morganella morganii cross reacting with Yersinia enterocolitica. (1988) (4)
Problems which address health related quality of life (HRQOL) in inflammatory bowel disease (IBD) (1998) (4)
Crohn's Disease Treated by Elemental Diet (1982) (4)
Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg) (2022) (4)
A case of achalasia diagnosed first on capsule endoscopy: find that hard to swallow? (2010) (3)
Helicobacter Pylori eradication therapy: getting research into practice. (2003) (3)
Re: Herrlinger et al.—pulmonary function abnormalities in inflammatory bowel disease (2002) (3)
"Best practice' for Helicobacter pylori eradication in the primary care setting. (2006) (3)
[Pan-European Registry on Helicobacter pylori management. Results from Ferencváros, Budapest, 2013-2019]. (2019) (3)
Endoscopic surveillance of premalignant gastric lesions (2003) (3)
Aminosalicylate as prophylaxis for Crohn's disease (2001) (3)
Temporomandibular joint dislocation: an unusual complication of upper gastrointestinal endoscopy. (2000) (3)
Novel therapeutic approaches to the management of Helicobacter pylori infection. (1998) (3)
Abstract form for the Irish Journal of Medical Science v workshop on gastroduodenal pathology and Helicobacter pylori July 5th — 7th 1992 — Dublin, Ireland (1992) (3)
Adult Lead Toxicity and Untreated Coeliac Disease (1988) (3)
Sa1256 Cost-Effectiveness of Episodic or Maintenance Infliximab Treatment Versus Standard Treatment in a Community-Based Incidence Cohort of Adult Ulcerative Colitis Patients With 10-Years Follow-up (2012) (3)
European Registry on Helicobacter pylori management (Hp-EuReg): First-line Therapy in Israel. (2021) (2)
How to Eradicate Helicobacter pylori and Prevent Reinfection (1990) (2)
Consensus Report Helicobacter pylori infection - The Maastricht III Current concepts in the management of (2007) (2)
Colonoscopy completion rates--are we prepared for a national screening programme? (2007) (2)
Salicylates, steroids and immnunosuppressants in Crohn's disease : Management of Crohn's disease (1994) (2)
Helicobacter pylori infection and gastric cancer: usefulness of screening high risk groups. (1995) (2)
: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease (2015) (2)
Gastric Polyps – Frequency,Types, Endoscopic Features and Associations (2004) (2)
W1312 Long Term Efficacy of the Second Biologic in the Management of Crohn's Disease. A Retrospective Survey on an English- Irish Cohort (2010) (2)
Concept of chemoprevention in colorectal cancer. (2009) (2)
P597 Effectiveness and safety of vedolizumab therapy in an ulcerative colitis cohort with significant prior anti-TNF exposure (2018) (2)
Antibiotic resistance trends of Helicobacter pylori naïve patients in the period 2013-2019: Analysis of the European Registry on H. pylori Management (Hp-Eu- Reg) (2020) (2)
Treatment of Helicobacter pylori infection (2003) (2)
Validation of Capsule Endoscopy Crohn's Disease Activity Score (CECDAI or Niv Score) – A Multi Center Prospective Study (2011) (2)
Living related liver transplantation : a Japanese experience and development of a checklist for donors ’ informed consent (2002) (2)
H. pylori eradication therapy: A discrepancy between current guidelines and clinical practice (1998) (2)
Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management (2020) (2)
Treatment of Helicobacter pylori (1998) (2)
Su1145 Detection of Helicobacter pylori and Antibiotic Resistance Using a Molecular Genetics-Based Approach in Human Faecal Samples (2015) (2)
A genetic locus of Helicobacter pylori inversely associated with gastric intestinal metaplasia. (2005) (2)
Challenges and Opportunities in IBD Clinical Trial Design. (2021) (2)
Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel (2016) (2)
Crohn's Disease: Treatment and Pathogenesis (1987) (2)
THE ROLE OF RIFAXIMIN IN IRRITABLE BOWEL SYNDROME DERIVED FROM A NETWORK META-ANALYSIS OF RANDOMIZED CONTROL TRIALS (2020) (2)
Nutrition and Crohn's Disease: An Overview (1990) (2)
Drug treatment of eosinophilic oesophagitis. (2012) (2)
The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg) (2021) (2)
Combined antrum and corpus biopsy protocol improves Helicobacter pylori culture success (2022) (2)
Empirical Second-Line Treatments in Europe: Results from the European Registry on H. Pylori Management (Hp-EuReg) (2021) (1)
Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease (2020) (1)
Tolerability of Shortened Infliximab Infusion in Scheduled Maintenance Therapy for IBD: A Prospective Multi-center European Cohort Study (2013) (1)
ERADICATION RATE OF HELICOBACTER PYLORI. AUTHORS' REPLY (1995) (1)
Predicting Screening Uptake by First‐Degree Relatives of Patients Diagnosed with Colorectal Cancer1 (2012) (1)
P254 Effect of standard treatment (ST) versus episodic (ET) or maintenance (MT) infliximab on healthcare cost (HC) and quality-adjusted life years (QALYs) in a community-based incidence cohort of adult Crohn's disease patients with 10 years follow-up (2012) (1)
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: the PROCTRIAL Consensus. (2022) (1)
Treatment of Helicobacter pylori Infection (2006) (1)
Letter: the ethics of using inferior regimens in H. pylori randomised trials – invited comment (2012) (1)
Isolated Active Ileitis: Serological and Genetic Profile (2011) (1)
Su1135 Pan-European Registry on H. pylori Management (HP-EuReg): Rescue Treatments (2015) (1)
An Audit of the Biopsy Protocol for Barretts Eosophagus – Need to Improve Compliance to Guidelines? (2004) (1)
Host cytokine responses toHelicobacter pylori: an important determinant of clinical outcome (2001) (1)
5-Aminosalicylates in inflammatory bowel disease: choosing the right dose. (2001) (1)
Novel therapies for Helicobacter pylori eradication (1998) (1)
128 Use of a biochip assaying 28 mutations in the KRAS, BRAF, TP53, and APC genes for detection of colorectal neoplasia (2010) (1)
Assessment of first-line eradication treatment in Greece: data from the European Registry on Helicobacter pylori management (Hp-EuReg) (2021) (1)
Colorectal Malignancy in a Prospective Irish Inflammatory Bowel Disease Population 15 Years Since Diagnosis: Comparison with the EC-IBD Cohort (2017) (1)
Educational needs in patients with irritable bowel syndrome (IBS): Implications for clinical management (1998) (1)
Small Intestinal Permeability in Patients with Inflammatory Bowel Disease (1983) (1)
Chromium-51-EDTA and technetium-99m-DTPA excretion for assessment of small bowel Crohn's disease (1984) (1)
Tu1327 Pan-European Registry on H. pylori Management (Hp-EuReg): Interim Analysis of Non-Bismuth Quadruple Concomitant Treatment (2016) (1)
Colonoscopy in Adults Younger Than 30 Years: A Blunt Instrument? (2009) (1)
Hepatic haemangiosarcoma in a patient with psoriasis and Crohn’s disease (1992) (1)
A new marker for colorectal cancer (2005) (1)
Increased mucosal mast cells - Evidence of an inflammatory response in IBS? (1999) (1)
Mo1580 Age, Smoking, Male Gender and Regular Aspirin use Predict Premalignant Conditions of the Stomach in a Low Gastric Cancer Prevalence Cohort (2012) (1)
Attempts to Eradicate Campylobacter pylori — Irish Experiences (1988) (1)
The role of defensive information processing in population‐based colorectal cancer screening uptake (2023) (1)
Helicobacter pylori : Phospholipase C and Haemolysis (1994) (1)
The Management of Duodenal Ulcer Relapse (1988) (1)
Improving surveillance for Barrett's oesophagus: Better to be looked over than be overlooked (2006) (1)
P641 Anxiety and depression in a prospective cohort of inflammatory bowel disease patients in Ireland (2014) (1)
Adalimumab in the Management of Crohn's Disease (CD) Patients with a Loss of Response to Infliximab (2006) (1)
182 Test, Treat and Re-Test. Who is Best at Checking for Helicobacter pylori Eradication After Apositive Urea Breath Test (UBT), Family Physicians or Gastroenterologists? (2010) (1)
OC-071 Comparison of Faecal M2-PK and Fit in Screening for Colonic Polyps in an average Risk Population (2013) (0)
METRONIDAZOLE AFFECTS HELICOBACTER PYLORI RELATED NONULCER DYSPEPSIA AND SYMPTOMS FROM CARBOHYDRATE MALABSORPTION. AUTHOR'S REPLY (1995) (0)
Rifabutin-Based Eradication Therapy after Failure of Standard First- and Second-Line Eradication Therapies in Helicobacter Pylori Infected Patients (2004) (0)
P257 - Genetic association between Crohn's disease and a marker located in the region of claudin 2 implicates the intestinal barrier as a primary risk factor in a Swedish population (2009) (0)
Activation of nuclear factor-kB (NF-kB) in diarrhoea predominant irritable bowel syndrome (2001) (0)
The Year in Helicobacter 2007 (2007) (0)
T1239 Infliximab in Inflammatory Bowel Disease: ‘Can We Heal Two Disease with One Drug?’ (2008) (0)
Table of Contents (2006) (0)
Polyp Surveillance - Experience from a Single Gastrointestinal Unit (2004) (0)
TREATMENT OF HELICOBACTER PYLOR (1998) (0)
M1102 ANCA, ASCA, Anti-OmpC and Anti-Cbir Antibodies Within An Irish Crohns Disease Cohort (2009) (0)
Gastric urease and peptic ulcer disease in Ireland in the 1940s — The Fitzgerald connection (2002) (0)
Eradication (1995) (0)
OC.08.2 EFFECTIVENESS OF EMPIRICAL FIRST-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (2021) (0)
Retraction Statement. Paper by Iebba V, Aloi M, Civitelli F, Cucchiara S: Digestive Diseases 2011;29:531-539 (DOI: 10.1159/000332969) (2014) (0)
Su1134 Pan-European Registry on H. pylori Management (HP-EuReg): Safety (2015) (0)
The plasticity region locus JHP947 is a pathogenicity marker found in Helicobacter pylori-associated gastric intestinal metaplasia (2005) (0)
Alpha 1 Anti Trypsin Levels in Asymptomatic Patients with Abnormal Liver Function Tests (2006) (0)
“Test, treat and confirm eradication” (2017) (0)
Dyspepsia: A test and treat management strategy (2001) (0)
Tu1214 The High Frequency of Adenomas Detected on Screening in Older Patients Warrants the Inclusion of This Cohort in National Programmes (2012) (0)
M1106 The Serological Profile of Isolated Active Ileitis (2009) (0)
Protein malnutrition in inflammatory bowel disease – An unrecognised problem? (2005) (0)
Endoscopy negative reflux: Any role for biopsy? (2000) (0)
P007 Rates of lactose malabsorption amongst Irish Caucasian inflammatory bowel disease patients (2012) (0)
Standards of colonoscopy in tallaght hospital; need for beyond the caecum (2006) (0)
Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg) (2022) (0)
The Bactericidal Effect of Tripotassium Dicitrato Bismuthate on Campylobacter Pyloridis in Patients with Duodenal Ulcer (1986) (0)
Contents Vol. 93, 2016 (2016) (0)
P401 Association between induction vedolizumab drug levels and therapy outcome in inflammatory bowel disease (2019) (0)
Helicobacter pylori and Duodenal Ulcer (1993) (0)
DISEASE CARD 4 / NOD 1 is not involved in inflammatory bowel disease (2002) (0)
Identification of differentially expressed genes of Heucobacter pylori in response to prolonged acid exposure (2000) (0)
P704 Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease (2019) (0)
web-guided ' Constant-care ' approach colitis : a randomised controlled trial of the E-health empowers patients with ulcerative (0)
Erratum: The microbiota in inflammatory bowel disease in different age groups (Digestive Diseases (2009) 27 (252-258) DOI: 10.1159/000228558) (2014) (0)
Changing Prevalence of Helicobacter pylori Infection in Elderly Dyspeptic Patients (2006) (0)
Helicobacter pylori infection. Implications for ulcer therapy in older patients. (1994) (0)
Increased inflammatory mediators in irritable bowel syndrome (IBS) (2005) (0)
Carditis: All H.pylori or an association with GERD? (2000) (0)
Stool DNA Testing – Not Quite There Yet? (2006) (0)
United European Gastroenterology Federation (2003) (0)
Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: results of a multidisciplinary international expert panel (EPACT II) (2009) (0)
Helicobacter pylori and gastric cancer. (1995) (0)
European Registry on Helicobacter pylori Management (Hp-EuReg): Most relevant results for clinical practice (2022) (0)
M1140 Helicobacter pylori Eradication Treatment is More Successful When Diagnosis is Made After Urea Breath Test Than After Rapid Urease Testing at Endoscopy in Patients With Dyspepsia (2010) (0)
United European Gastroenterology joins the Biomedical Alliance for Health Research (2014) (0)
178 Changing Patterns of Clarithromycin and Metronidazole Resistance Amongst Helicobacter pylori Strains in a Reference Centre (2010) (0)
Mucosal Enzyme Abnormalities in Rectal Biopsy in Inflammatory Bowel Disease (1982) (0)
OC.08.4 ANTIBIOTIC RESISTANCE TRENDS OF ITALIAN H. PYLORI NAÏVE PATIENTS BETWEEN 2013-2020: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (2021) (0)
685 Longitudinal Changes in Body Mass Index and Abdominal Obesity in Crohn's Disease - Associations With Inflammatory Markers and Disease Course (2013) (0)
Su1494: REDUCED SEROLOGICAL RESPONSE TO COVID-19 VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; EARLY RESULTS OF THE VARIATION STUDY (VARIABILITY IN RESPONSE IN IBD AGAINST SARS-COV2-IMMUNISATION) (2022) (0)
Eradication of Helicobacter pylori: Summary of Workshop (1993) (0)
Adenomatous polyps and colorectal cancer in relation to serum vitamin E and related antioxidants (1990) (0)
P109 CIGARETTE SMOKING, DISEASE LOCATION AND SEVERITY IN CROHN'S DISEASE (2008) (0)
Patients with Azathioprine/6-Mercaptopurine Refractory Inflammatory Bowel Disease are more prone to 6-Thioguanine Related Toxicity (2004) (0)
Tu1335 European Registry on H. pylori Management (HP-EuReg) in Spain: Interim Analysis in First and Second Line Therapies (2016) (0)
Absolute leukocyte count and its correlation with thiopurine methyl transferase (TPMT) activity in inflammatory bowel disease (IBD) patients receiving AZAthioprine (Aza)/6-mercaptopurine (6MP) (2003) (0)
The role of nutrition in liver disease. (1996) (0)
Research on digestive and liver diseases: a priority for Europe – The societal importance of gastrointestinal diseases and research (2013) (0)
Issue Information – TOC ‐ Masthead (2016) (0)
Diversity of the cag7 and cag2 genes in H. pylori (2001) (0)
SNP mapping of the HLA class III region confirms existence of an extended haplotype in coeliac disease (2003) (0)
Metronidazole affectsHelicobacter pylori related nonulcer dyspepsia and symptoms from carbohydrate malabsorption (1995) (0)
AF.24 CHARACTERISTICS OF EMPIRICAL FIRST- AND SECOND-LINE TREATMENT BETWEEN 2013-2020: ITALIAN DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (2021) (0)
Correlation between severity of villous atrophy and gastric mucosal inflammation — an observational case control study (2003) (0)
OC.08.5 EFFECTIVENESS OF EMPIRICAL SECOND-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (2021) (0)
Re: Scolapio et al.--Normal endoscopy, dysphagia, and esophageal dilation. (2001) (0)
63 10 year follow-up study of the long term effects of ANTI-TNF therapyon bone metabolism in a cohort of ANTI-TNF naïve IBD patients (2017) (0)
ULCERATIVE colitis and pregnancy. (2011) (0)
carcinoma . progression from normal mucosa to gastric Gastric epithelial cell kinetics in the (2006) (0)
PGI10 COST EFFECTIVENESS OF PROTON PUMP INHIBITOR TRIPLE THERAPY REGIMENS FOR HELICOBACTER PYLORI ERADICATION IN THE PRIMARY CARE SETTING IN IRELAND (2005) (0)
inflammatory bowel disease . biopsies from patients with immunocytochemical studies in rectal concentrations and Vasoactive intestinal peptide (2006) (0)
S1187 Genetic Association Between Crohn's Disease and a Marker Located in the Region of Claudin 2 Implicates the Intestinal Barrier As a Primary Risk Factor in a Swedish Population (2009) (0)
P216 IBD Patients' Need in Quality of Health Care (QoHC) ECCO Consensus (2008) (0)
Helicobacter pylori eradication for dyspepsia is clinically useful (2000) (0)
CARD4/NOD1 in inflammatory bowel disease. (2002) (0)
"This is the pre-peer reviewed version of the following article: Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel (2015) (0)
60 Tailored therapy for rescue treatment of helicobacter pylori infection (2017) (0)
Activation of nuclear factor-kappa B (NF-kappa B)in diarrhoea predominant irritable bowel syndrome (2001) (0)
Effectiveness of first and second‐line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management (2022) (0)
Elemental Diet in the Treatment of Inflammatory Bowel Disease (2018) (0)
Prevalence of Helicobacter pylori: An Irish Experience in a Dublin Associated Teaching Hospital over a Six Year Period (2006) (0)
Prevalence and Evolution of Hypertransaminasemia in the Newly Diagnosed Coeliac Patients: An Irish Experience in a Dublin Hospital (2006) (0)
Helicobacter pyloni (0)
Clinical Application of Antibiotics in Eradicating Helicobacter pylori (1994) (0)
Re: Herrlinger et al.--Pulmonary function abnormalities in inflammatory bowel disease. (2002) (0)
309 Prevalence of Hypertension in a Hereditary Haemachromatosis Population and the Influence of Treatment on Their Cardiovascular Risk (2010) (0)
A Descriptive Study of the Characteristics of People with Helicobacter pylori Infection (1993) (0)
P244 15 Years on: The Outcome of the Irish EC-IBD Cohort (2008) (0)
Multiple organ dysfunction following ingestion of methylenedioxy-amphetamine (MDA) (1995) (0)
P463 Long-term effects of anti-TNF therapy on bone metabolism (2018) (0)
Introduction from the President (2013) (0)
Sulfasalazine: Side effects (1984) (0)
EP1019: THE EFFECTS OF THE COVID-19 PANDEMIC ON PRESENTATIONS AND DIAGNOSIS OF UPPER GI AND HEPATOPANCREATICOBILIARY MALIGNANCIES (2022) (0)
Su1136 Pan-European Registry on H. pylori Management (HP-EuReg): Interim Analysis of 8,271 Patients (2015) (0)
Distribution of polyps and cancer in the colon (2005) (0)
Localization of HLA and IA Antigens and β2 Microglobulins in Human Small Intestinal Mucosal Cells (1983) (0)
Management of Helicobacter pylori infection — a review of the available regional and national guidelines (2003) (0)
[When should Helicobacter pylori be eradicated?]. (1994) (0)
Undernutrition and Reduced Muscle Funcion Is Common in Young Patients with Crohns Disease (Cd) (2006) (0)
Current trends in the treatment of H. pylori infection in Ukraine: results of the European Registry on Helicobacter pylori Management (Hp EuReg) (2022) (0)
Detection of premalignant lesions in first degree relatives of gastric cancer: Endoscopy or serodiagnosis? (2003) (0)
Multiple drug resistance gene (MDRI) polymorphisms and steroid resistance in inflammatory bowel disease (IBD) (2003) (0)
Investigations of Asymptomatic Patients with Abnormal Liver Function Tests (LFT's) in the Outpatient Setting. Experience and Cost Analysis in the Real World (2006) (0)
Are we able to treat inflammatory bowel disease with diet (2005) (0)
Il-1b polymophisms are NOT associated with Helicobacter pylori positive intestinal metaplasia (2003) (0)
T2069 Effects of Tryptase and Mast Cells on Intestinal Permeability and Tight Junction Proteins: Implications for the Pathogenesis for Irritable Bowel Syndrome (IBS) (2010) (0)
Infliximab in Patients with Moderate to Severe Ulcerative Colitis with a Failed Response to Medical Therapy (2006) (0)
Eradication rate of Helicobcter pylori. (1995) (0)
Le cancer gastrique : une conséquence à long terme de l'infection à Helicobacter pylori ? (1994) (0)
Retraction Statement. Paper by Krznarić Ž, Vranešić Bender D, Kunović A, Kekez D, Štimac D: Digestive Diseases 2012;30:196-200 (DOI: 10.1159/000336965) (2014) (0)
Helicobacter pylori infection and gastric cancer (2005) (0)
Dyspepsia Prescribing by Primary Care Physicians (PCPS) – The Impact of an Open Access Urea Breath Test Service (2004) (0)
A proposal for future Helicobacter pylori eradication guidelines (2003) (0)
The Effect of Eicosapentaenoic Acid on Treatment and Neutrophil Function in Inflammatory Bowel Disease (1986) (0)
Innovations in Gastro-Intestinal Endoscopy: Endoscopic Antireflux Therapies for Gastro-Oesophageal Reflux Disease (2003) (0)
W1882 Identification of Smoking As a Risk Factor for Gastric Intestinal Metaplasia (2008) (0)
Investigations into substance P and mast cells in functional dyspepsia (2001) (0)
Re: Scolapio et al.—normal endoscopy, dysphagia, and esophageal dilation (2001) (0)
Introduction (2003) (0)
154 Significant Psychological Co-Morbidity Exists in Irritable Bowel Syndrome: A Case-Control Study Using the Irish Hse-Pcrs Pharmacy Reimbursement Database (2008) (0)
P076 Role of Increasing Body Mass Index in Adults with Quiescent Crohn's Disease (2008) (0)
P594 Ustekinumab treatment effectiveness in clinical practice - a multicentre retrospective review of long-term outcomes in Crohn's disease. (2017) (0)
High Prevalence of Vitamin D Insufficiency in Inactive Crohn's Disease (CD) (2006) (0)
helicobacter pylori cagA, cagE and BabA2 genotypes in patients with intestinal metaplasia and gastritis (2006) (0)
PRM38 Estimation of a Markov Chain for Crohn's Disease and Classification of Patients Into Disease Phenotypes, in Eight Countries Using Individual Longitudinal Data Aggregated Over Time (2012) (0)
P042 High Prevalence of Vitamin D Deficiency in Crohn's Disease in Wintertime: Spectrum of a Wider Public Health Problem? (2008) (0)
Virulence factors predict long-term clinical efficacy of eradication therapy in nonulcer dyspepsia (NUD) (2000) (0)
Calcium intake in crohn's disease (CD): Are we meeting the nutritional guidelines? (2005) (0)
Prevalence of overweight and obesity in patients with Crohn's disease in Western countries and Japan (2013) (0)
Introduction (2003) (0)
Screening for colorectal cancer (2007) (0)
Helicobacter pylori . mucosa with aspirin in the absence of Early ultrastructural changes of antral (0)
Sa1570 Barrett's Metaplasia: Underdiagnosed At Endoscopy (2011) (0)

This paper list is powered by the following services:

Colm A. O’morain's Academic­Influence.com Rankings

Colm A. O’morain's Degrees

Why Is Colm A. O’morain Influential?

Colm A. O’morain's Published Works

Published Works

Colm A. O’morain's AcademicInfluence.com Rankings